SAB Biotherapeutics Inc (SABS) — Cash Flow Quality Index
SAB Biotherapeutics Inc (SABS) has a Cash Flow Quality Index of -2.44x as of September 2025. Operating cash flow of $-13.05 Million is below net income of $5.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore SAB Biotherapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
SAB Biotherapeutics Inc Cash Flow Quality Index (2020–2025)
Historical Cash Flow Quality Index for SAB Biotherapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see how efficiently does SAB Biotherapeutics Inc generate cash.
Annual Cash Flow Quality Index for SAB Biotherapeutics Inc (2020–2025)
Year-by-year earnings quality comparison for SAB Biotherapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -3.37x | $-44.78 Million | $13.27 Million | ▼ -778.3% |
| 2020 | 0.50x | $10.00 Million | $20.12 Million | — |